For instance, neoadjuvant chemotherapy of HER2-negative BC may include different combinations of cytostatic agents such as anthracyclines, cyclophosphamide, and taxanes[7] that can be administered in different sequential orders[8]. This evidence concerns the gene ERBB2 and breast cancer.